Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Medical University of Vienna
Information provided by (Responsible Party):
Philipp Riss, Medical University of Vienna Identifier:
First received: September 8, 2009
Last updated: March 14, 2016
Last verified: March 2016

Primary Hyperparathyroidism (pHPT) increases bone turnover and resorption and thus calcium efflux out of bone. After successful surgical treatment of pHPT, bone takes up calcium again which may result in secondary hyperparathyroidism or even "hungry bone syndrome". Until today there are no studies about this problem helping to develop recommendations or guidelines how to prevent these symptoms.

Study hypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents hungry bone- syndrome and improve bone-turnover markers (osteoporosis protection).

Condition Intervention Phase
Primary Hyperparathyroidism
Bone Metabolism
Drug: Calcium and vitamin D
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Parathyroid hormone [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • BMD of lumbar spine, femoral neck and radius [ Time Frame: 1 year ]
  • Adverse effects calcium or vitamin D [ Time Frame: 1 year ]
  • Other biochemical markers of bone metabolism [ Time Frame: 1 year ]

Estimated Enrollment: 80
Study Start Date: September 2009
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Calcium and vitamin D
Drug: Calcium and vitamin D
1000mg calcium per day 800 IE vitamin D per day
No Intervention: No treatment (control)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women
  • Male patients
  • Biochemically proven PHPT, PTX planned
  • No evidence for osteoporosis

Exclusion Criteria:

  • Postoperative hypocalcemia needing substitution with calcium and vitamin D/ 1-25-OH-Vitamin D
  • Cancer (lung, breast, prostatic, parathyroid cancer and thyroid carcinoma >1cm)
  • Persisting or recurrent PHPT (postoperative hypercalcemia)
  • Four-gland hyperplasia
  • Multiple endocrine neoplasia (MEN) or hereditary PHPT
  • Familial hypercalciuric hypercalcaemia (Ca/creatinine ratio < 0.01)
  • Phenylketonuria
  • Renal impairment (creatinine clearance <30ml/h)
  • Severe hepatic disorder
  • Severe systemic disorder
  • Thyroid dysfunction
  • Immobilisation
  • Intake of drugs with potential effects on BMD like glucocorticoids, lithium, estrogen-replacement therapy, selective Estrogen-receptor modulators (sERMs), bisphosphonates in the last three months
  • Intake of drugs containing digoxin or digitoxin
  • Known allergy against any component of the study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00973336

Contact: Philipp Riss, MD +43140400 ext 5621
Contact: Bruno Niederle, Professor, MD +43140400 ext 6943

Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Philipp Riss, MD    +43140400 ext 5621   
Sub-Investigator: Philipp Riss, MD         
Principal Investigator: Bruno Niederle, Prof., MD         
Sub-Investigator: Reza Asari, MD         
Sub-Investigator: Christian Scheuba, MD         
Sub-Investigator: Katharina Kerschan-Schindl, Prof., MD         
Sub-Investigator: Peter Pietschmann, Prof., MD         
Sub-Investigator: Christian Bieglmayer, Prof., PhD         
Sub-Investigator: Martin B Niederle, MD         
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Bruno Niederle, Prof., MD Medical University of Vienna, Department of Surgery
  More Information

Responsible Party: Philipp Riss, Assistent Professor, Medical University of Vienna Identifier: NCT00973336     History of Changes
Other Study ID Numbers: PHPT02_2008
Study First Received: September 8, 2009
Last Updated: March 14, 2016

Keywords provided by Medical University of Vienna:
postoperative follow-up

Additional relevant MeSH terms:
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases
Vitamin D
Calcium, Dietary
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on May 25, 2017